01/07/15
Vtesse: First Spin-out from Rare Disease Accelerator Cydan
Today Vtesse, a newly formed biopharma company, announced that it has raised $25 million to develop novel treatments for rare diseases. It’s a…
Biopharma, Healthcare, Investment, Strategy
Read Content